Pfizer Inc said on Wednesday the first formal late-stage trial of its approved treatment for advanced breast cancer, Ibrance, was stopped early after the medicine met its goal of delaying progression of the disease in previously treated patients. J.P.Morgan analyst Chris Schott said in a research note that the successful trial results should boost demand for the recently approved treatment, which works differently than approved medicines and has blockbuster sales potential. Pfizer said the Phase 3 study, called Paloma 3, was halted after an independent data monitoring board determined that Ibrance, also known as palbociclib, had proven its effectiveness among patients with advanced disease who had previously been treated with anti-estrogen drugs. Patients taking Ibrance in combination with AstraZeneca Plc's Faslodex (fulvestrant), a widely used treatment to block estrogen, were deemed to have fared better in terms of disease progression than those taking Faslodex alone.
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment